AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio is viewed positively because Jemperli is demonstrating strong commercial momentum, with global net sales of $331M in 2Q26, $644M in 1H26, and $1.4B annualized in 4Q25, while management still expects more than $390M of annualized royalties as early as 2029 and potential upside toward ~$475M after the Sagard paydown. The outlook is further supported by regulatory de-risking: Health Canada accepted the rectal cancer filing under Project Orbis and NOC/c, the FDA granted priority review with a February 2027 PDUFA date, and AZUR-1 showed meaningful and sustained clinical complete responses for at least 12 months. The company also has multiple longer-dated catalysts and durable patent protection through 2035 in the U.S., 2036 in Europe, and 2037 in Japan, which support a long runway for royalty growth and value creation.

AnaptysBio is a clinical-stage biotech with a fragile thesis because its value depends heavily on uncertain trial outcomes, regulatory approvals, and partner-driven royalty streams rather than established product sales. Ongoing litigation with GSK, risk around Jemperli’s commercial uptake, and possible setbacks in the currently submitted BLA for imsidolimab could all erode royalty upside, while weak clinical or financial results would pressure overall valuation. Although additional capital is not currently projected, the company still faces the sector’s high funding needs and could be forced to raise money if development, regulatory, or competitive risks worsen.